EEG Analysis and Animal Behavior in CNS Drug Development

Presented by Ruiben Feng, PhD, Executive Director, Neurobiology and Neuropharmacology at Shanghai ChemPartner.


EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and compounds will exhibit clinical efficacy early in preclinical development. EEG and relevant analyses have been very useful in the drug development process in the context of several major central nervous system (CNS) diseases including Alzheimer’s disease, epilepsy, sleep/wake disorders, schizophrenia, depression, attention deficit, hyperactivity disorder, and pain. Additionally, EEG-based signatures represent promising preclinical screens to quickly determine CNS penetration, drug-target engagement, evidence of efficacy, pharmacokinetic/pharmacodynamic profile, CNS safety and toxicity, and pro-convulsant risk.

In this webinar, the featured speaker will review the EEG analysis, related optimization parameters, and candidate compound selection as well as case studies where EEG-based signatures in correlation with animal behavior could validate the EEG as the endpoint for a set of translatable biomarkers bridging preclinical and clinical programs.

Join this webinar to gain insights into EEG analysis as physiological endpoints to facilitate drug discovery for CNS diseases.

Keep watching…

Assay Platforms for PROTAC in Drug Discovery and Beyond

Assay Platforms for PROTAC in Drug Discovery and Beyond

Presented by Yuzhou Xu, Senior Director of Biology and Pharmacology at ChemPartner. Abstract: Discover a groundbreaking webinar delving into the in vitro assays for proteolysis targeting chimera (PROTAC). PROTACs are being developed more and more for many kinds of...


1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203


Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000